Broad Institute signs deals to boost medical research

The Broad Institute of Harvard and MIT has committed itself to tackling complex therapeutic challenges concerning unmet medical needs, while also signing a deal on technology.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Broad Institute enters talks for CRISPR licensing pool

11 July 2017 The Broad Institute of MIT and Harvard has announced that it has entered talks to create a worldwide licensing pool for CRISPR/Cas9 patents.

Americas

Broad Institute and UCB to face off at CRISPR interference hearing

1 December 2016 An interference proceeding on the patent rights to CRISPR/Cas9 will take place on December 6, with the judges setting the definition of the disputed invention as “the use of CRISPR in a method in a eukaryotic cell”.

More features

To disclose or not: Pharma patents face new AI reality

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

Broad Institute signs deals to boost medical research

More on this story

Editor's picks

Editor's picks

More features